| Objective To investigate the effect of levosimendan on cardiac function, MACE events and adverse reactions in elderly patients with acute heart failure. Methods From January 2017 to July 2018, 64 cases of elderly patients with acute heart failure treated in the Cardiovascular Department of Zhoukou Central Hospital were selected and equally divided into two groups according to the admission order. The control group received routine treatment, while the observation group received the levosimendan based on routine treatment. The efficacy of two groups before treatment and one week after treatment, cardiac function changes (LVESD, LCEDD), MACE events (heart failure, malignant arrhythmia, cardiac death, total MACE events) and adverse reactions (blood pressure reduction, arrhythmia, headache) were observed. Results There was significant difference in BNP as well as LVEF, SV LVESD and LVEDD differentials between the two groups before treatment and one week after treatment (P<0.05). The incidence of MACE events in observation group was 37.5%, lower than 65.6% in control group, and the rate of adverse reactions in observation group was 9.38%, lower than 62.5% in control group, and the difference was statistically significant (P<0.05). Conclusions Levosimendan can effectively ameliorate the cardiac function of patients and reduce the effects of MACE events and adverse reactions in elderly patients with acute heart failure. |
